Trinity Biotech Launches Global Expansion of High-Capacity Column System for FDA-Approved HbA1c Testing Following Regulatory Approvals | Intellectia.AI
Trinity Biotech Launches Global Expansion of High-Capacity Column System for FDA-Approved HbA1c Testing Following Regulatory Approvals
Written by Emily J. Thompson, Senior Investment Analyst
Company Overview: Trinity Biotech plc is a biotechnology company focused on diabetes management and human diagnostics, recently enhancing its product offerings with a next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer, now available in over 10 countries.
Market Potential: The global HbA1c market is valued at over $2 billion and is projected to exceed $3.5 billion by 2030, driven by the rising prevalence of diabetes, positioning Trinity Biotech for significant growth opportunities.
Operational Improvements: The upgraded column system increases testing capacity by up to four times, reduces downtime, and enhances operational efficiency, which is expected to lead to broader adoption and increased recurring revenue for the company.
Future Outlook: Trinity Biotech aims to expand its market presence and innovation in diabetes care, with ongoing collaborations with customers and regulatory authorities to enhance product availability in additional countries.
TRIB
$0.94+Infinity%1D
Analyst Views on TRIB
About TRIB
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
